ReviewNeurosurgical review2008
Molecular strategies for the treatment of malignant glioma--genes, viruses, and vaccines.
Review in Neurosurgical review, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 46 citations in OpenAlex.
- Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas.Science translational medicine · 2023Article
- Against the Resilience of High-Grade Gliomas: Gene Therapies (Part II).Brain sciences · 2021Review
- A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.Cancer immunology, immunotherapy : CII · 2019Article
- Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma.Journal of immunology research · 2016Article
- Vaccine therapies in malignant glioma.Current neurology and neuroscience reports · 2015Review
- Intratumoral INF-γ triggers an antiviral state in GL261 tumor cells: a major hurdle to overcome for oncolytic vaccinia virus therapy of cancer.Molecular therapy oncolytics · 2015Article
- Vaccine therapies for patients with glioblastoma.Journal of neuro-oncology · 2014Review
- Gene therapy for malignant glioma.Molecular and cellular therapies · 2014Review
- Newcastle disease virus interaction in targeted therapy against proliferation and invasion pathways of glioblastoma multiforme.BioMed research international · 2014Review
- Article
- Strategies in gene therapy for glioblastoma.Cancers · 2013Article
- Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.Cancer gene therapy · 2012Article
- Gene therapy and targeted toxins for glioma.Current gene therapy · 2011Review
- Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas.Current cancer drug targets · 2010Review
- Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination model.Journal of neuroimmunology · 2010Article
- Article
- EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Current molecular pharmacology · 2010Review
- Improving seroreactivity-based detection of glioma.Neoplasia (New York, N.Y.) · 2009Article
- Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009Article
- A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy.The journal of gene medicine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
The standard treatment paradigm of surgery, radiation, and chemotherapy for malignant gliomas has only a modest effect on survival. It is well emphasized in the literature that despite aggressive multimodal therapy, most patients survive approximately 1 year after diagnosis, and less than 10% survive beyond 2 years. This dismal prognosis provides the impetus for ongoing investigations in search of improved therapeutics. Standard multimodal therapy has largely reached a plateau in terms of effectiveness, and there is now a growing body of literature on novel molecular approaches for the treatment of malignant gliomas. Gene therapy, oncolytic virotherapy, and immunotherapy are the major investigational approaches that have demonstrated promise in preclinical and early clinical studies. These new molecular technologies each have distinct advantages and limitations, and none has yet demonstrated a significant survival benefit in a phase II or III clinical trial. Molecular approaches may not lead to the discovery of a "magic bullet" for these aggressive tumors, but they may ultimately prove synergistic with more conventional approaches and lead to a broadening of the multimodal approach that is the current standard of care. This review will discuss the scientific background, therapeutic potential, and clinical limitations of these novel strategies with a focus on those that have made it to clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.